



## MEETING AGENDA

### Pharmacy and Therapeutics Committee

Virtual Meeting

May 21, 2025 12:00PM – 5:00PM

Registration: <https://teams.microsoft.com/meet/221045229711?p=de1QrGrujCNSpsDXng>

Meeting ID: 221 045 229 711 Passcode: bU3FX9ep

Dial in by phone: [+1 480-561-5941](tel:+14805615941), [909857889#](tel:+1909857889) United States, Phoenix

[Find a local number](#) Phone conference ID: 909 857 889#

| TIME     | TOPIC/PRESENTER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12:00 PM | <b>Welcome &amp; Introductions:</b> Suzanne Berman, RPH, AHCCCS Pharmacy Director                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 12:10 PM | <b>Minutes Review &amp; Vote - P&amp;T January 15, 2025:</b> Suzanne Berman                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 12:15 PM | <b>Legislative Report Update:</b> Suzi Berman                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 12:30 PM | <p><b>Supplemental Rebate Drug Class Review:</b> Clinical review by Umang Patel, PharmD, Prime Therapeutics</p> <ol style="list-style-type: none"> <li><b>1. Analgesics, Long-Acting Narcotic</b> <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li><b>2. Antibiotics, Inhaled</b> <ol style="list-style-type: none"> <li>a. Public Testimony – Oral:                             <ol style="list-style-type: none"> <li>i. Michelle Ratkiewicz</li> </ol> </li> </ol> </li> <li><b>3. Antimigraine Agents, Other</b> <ol style="list-style-type: none"> <li>a. Public Testimony – Written:                             <ol style="list-style-type: none"> <li>i. Mandeep Sohal</li> </ol> </li> </ol> </li> <li><b>4. Antipsychotics, Atypical Long-Acting Injectable</b> <ol style="list-style-type: none"> <li>a. Public Testimony – Oral:                             <ol style="list-style-type: none"> <li>i. Stefan Luft</li> <li>ii. Mandeep Sohal</li> <li>iii. Chung Trinh</li> </ol> </li> <li>b. Public Testimony – Written:                             <ol style="list-style-type: none"> <li>i. Carrie Bowman</li> <li>ii. Josie Cooper</li> <li>iii. Casey Hollingsworth</li> <li>iv. Tammy Hostetler</li> <li>v. Miguel Tosado</li> </ol> </li> </ol> </li> <li><b>5. Antipsychotics, Oral Atypical (2nd Gen Only)</b> <ol style="list-style-type: none"> <li>a. Public Testimony – Oral:                             <ol style="list-style-type: none"> <li>i. Amy Filleman</li> <li>ii. Scott Gilman</li> </ol> </li> <li>b. Public Testimony – Written:                             <ol style="list-style-type: none"> <li>i. David Delawder</li> </ol> </li> </ol> </li> </ol> |

## MEETING AGENDA

|  |                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <ul style="list-style-type: none"> <li>ii. Christine Gonzalez</li> <li>iii. Cindy Komar</li> <li>iv. Kristen Pyland</li> <li>v. Kristina Sabetta</li> <li>vi. Tabitha Salzer</li> </ul>                                                                                                                                                                                                                              |
|  | <p><b>6. Colony Stimulating Factors</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul>                                                                                                                                                                                                                                                                                              |
|  | <p><b>7. COPD Agents</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul>                                                                                                                                                                                                                                                                                                             |
|  | <p><b>8. Cytokine and CAM Antagonists</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Amy Hale</li> </ul> </li> <li>b. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Mandeep Sohal</li> </ul> </li> </ul>                                                                                                               |
|  | <p><b>9. Glucagon Agents</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Rachel Shubitz</li> </ul> </li> </ul>                                                                                                                                                                                                                               |
|  | <p><b>10. Glucocorticoids, Inhaled</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Christine Dube</li> </ul> </li> </ul>                                                                                                                                                                                                                        |
|  | <p><b>11. Growth Hormone</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Joel Hahnke</li> <li>ii. Chirag Kapadia</li> </ul> </li> </ul>                                                                                                                                                                                                      |
|  | <p><b>12. Hepatitis C Agents</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul>                                                                                                                                                                                                                                                                                                     |
|  | <p><b>13. Hypoglycemics (Insulin and Related Agents)</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul>                                                                                                                                                                                                                                                                             |
|  | <p><b>14. Hypoglycemics, Incretin Mimetics/Enhancers</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Justen Caleca</li> <li>ii. Lixian Zou</li> </ul> </li> <li>b. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Lory Baraz</li> <li>ii. Edgardo Laurel</li> </ul> </li> </ul>                                          |
|  | <p><b>15. Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma)</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Debby Ham</li> <li>ii. Carla McSpadden</li> <li>iii. Krystle Thai</li> </ul> </li> <li>b. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Christine Dube</li> </ul> </li> </ul> |
|  | <p><b>16. Movement Disorders</b></p>                                                                                                                                                                                                                                                                                                                                                                                 |

## MEETING AGENDA

|                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                | <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Ray Kong</li> </ul> </li> <li>b. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Mandeep Sohal</li> </ul> </li> </ul> <p><b>17. Multiple Sclerosis Agents</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Shirley Quach</li> <li>ii. Payal Tejani</li> </ul> </li> <li>b. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Stephanie Niemi-Olson</li> <li>ii. Michael Robers</li> <li>iii. Naveed Vehra</li> </ul> </li> </ul> <p><b>18. Opioid Dependence Treatments</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Megan Penner</li> </ul> </li> </ul> <p><b>19. Pancreatic Enzymes</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony: None</li> </ul> <p><b>20. Stimulants and Related Agents</b></p> <ul style="list-style-type: none"> <li>a. Public Testimony – Oral: <ul style="list-style-type: none"> <li>i. Patrick Harvey</li> </ul> </li> <li>b. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Kristina Sabetta</li> <li>ii. Joseph Werther</li> </ul> </li> </ul> |
| <b>3:00 PM</b> | <p><b>New Drug Reviews: Umang Patel</b></p> <ul style="list-style-type: none"> <li>1. Alyftrek</li> <li>2. Crenessity <ul style="list-style-type: none"> <li>a. Public Testimony – Written: <ul style="list-style-type: none"> <li>i. Ray Kong</li> </ul> </li> </ul> </li> <li>3. Tryngolza</li> <li>4. Tryvio</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>3:15 PM</b> | <b>Break &amp; Executive Session: Nina Bandali, PharmD, Prime Therapeutics</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>4:30 PM</b> | <b>Public Therapeutic Class Votes: Hind Douiki</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>4:45 PM</b> | <b>Biosimilar Update: Suzi Berman</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>5:00 PM</b> | <p><b>Meeting Adjournment</b></p> <p>2025 Meeting Dates: October 22</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |